Insights into the pathogenesis and pathogenicity of cerebral amyloid angiopathy

Research output: Contribution to journalReview article (Academic Journal)peer-review

65 Citations (Scopus)


Amyloid-beta (Abeta) cerebral amyloid angiopathy (CAA) affects most Alzheimer's disease (AD) patients and ~30% of otherwise-normal elderly people. APOE epsilon 4 is a major risk factor for CAA in AD. Neurons are probably the source of the vascular Abeta. CAA develops when Abeta is deposited in the vessel walls along or across which it normally passes into the CSF and bloodstream. Vascular deposition is facilitated by factors that increase Abeta40:Abeta42, impede perivascular passage of Abeta or raise its concentration. The levels of some Abeta-degrading enzymes are reduced in AD patients with CAA. However, angiotensin-converting enzyme activity is increased and may act via angiotensin II to increase transforming growth factor beta1, a potent inducer of ECM synthesis. CAA is a cause of intracerebral haemorrhage and cerebral ischaemic damage. In AD, neuritic degeneration is accentuated around Abeta-laden vessels. Rarely, CAA is associated with angiitis. The balance between parenchymal and cerebrovascular degradation of Abeta, and regulation of perivascular extracellular matrix production, are likely to be key determinants of Abeta distribution and pathogenicity within the brain.
Translated title of the contributionInsights into the pathogenesis and pathogenicity of cerebral amyloid angiopathy
Original languageEnglish
Pages (from-to)4778 - 4792
Number of pages15
JournalFrontiers in Bioscience
Publication statusPublished - Jan 2009

Structured keywords

  • Dementia Research Group


Dive into the research topics of 'Insights into the pathogenesis and pathogenicity of cerebral amyloid angiopathy'. Together they form a unique fingerprint.

Cite this